| Jennifer Corn, | |
|
1101 Westloop Pl, Manhattan, KS 66502-2837 | |
| (785) 539-9454 | |
| Not Available |
| Full Name | Jennifer Corn |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1101 Westloop Pl, Manhattan, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063813624 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1-12896 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Corn, 1101 Westloop Pl, Manhattan, KS 66502-2837 Ph: () - | Jennifer Corn, 1101 Westloop Pl, Manhattan, KS 66502-2837 Ph: (785) 539-9454 |
News Archive
Senate conferees in negotiations on the farm bill have withdrawn a proposal that the conference report include a provision under which physicians could not refer patients to specialty hospitals in which they have a financial interest amid opposition from House conferees and others, CongressDaily reports.
CDC Director Thomas Frieden, who currently is visiting India and who previously worked with the Indian government assisting in tuberculosis (TB) control, praised the country's "progress in controlling tuberculosis and tobacco use" on Monday during a speech to health practitioners and policymakers, according to the Wall Street Journal's "India Real Time" blog.
In a recent editorial, the Editor-in-Chief, Dr. James J James statess that there are currently two potential public health crises in the US.
Leading up to the London Summit on Family Planning taking place July 11, the Bill & Melinda Gates Foundation's "Impatient Optimists" blog published several posts addressing family planning issues.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
› Verified 4 days ago
John Clyde, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 101 Bluemont Ave, Manhattan, KS 66502 Phone: 785-776-4841 Fax: 785-776-4842 | |
Casey D Andrews, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 325 Bluemont Ave, Manhattan, KS 66502 Phone: 785-776-9787 Fax: 785-776-9862 | |
Evan Riordan, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 800 Commons Pl, Manhattan, KS 66503 Phone: 785-770-3871 | |
Constance Mcconnell, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 325 Bluemont Ave, Manhattan, KS 66502 Phone: 785-775-9787 | |
Mr. Von J Bolton, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2429 Claflin Rd, Manhattan, KS 66502 Phone: 785-539-2345 Fax: 785-539-3494 | |
Dr. Jane Eunyoung Mauro, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3033 Irene Cir, Manhattan, KS 66502 Phone: 206-412-1010 |